Business Wire

The Next Evolution of the JOST KKS Automatic Coupling System: the KKS-U Connector

16.5.2023 11:00:00 EEST | Business Wire | Press release

Share

In April 2021 JOST introduced the revolutionary KKS automatic coupling system. It enables the driver to couple and uncouple the semi-trailer via remote control – automatically, safely and quickly. Climbing out of the cabin, cranking down the landing gear and manually connecting the spiral cable, air and brake connections are all a thing of the past. Now JOST presents the latest development of the KKS: the KKS-U Connector which is retrofittable to existing trailers that already are on the roads of this world.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The KKS-U Connector is easily retrofittable to trailers that are already in use. (Photo: JOST)

Coupling and uncoupling a trailer is still a lengthy, expensive and hazardous procedure. The truck driver has to be aware of many different things, each of which are time-consuming and pose a hazard to health and safety. As the global market leader for fifth wheel couplings and landing gears, JOST is providing a smart solution for the future of coupling with its KKS automatic coupling system. The KKS 42 fifth wheel coupling, Modul E-Drive electric landing gear, sensor coupling system, 3-sensors, LubeTronic automatic lubrication system, KKS remote control and the ISO 13044-2-certified KKS connector all combine to form an innovative system for the coupling process.

KKS-U Connector retrofittable to existing trailers

Until now the KKS was a solution for mixed fleets and new trailers. JOST has now further developed the system and is introducing the new KKS-U Connector to the market. Fitted to the underside of the trailer, the KKS-U Connector is an alternative installation variant and enables fleet operators to equip existing trailers easily with the KKS. It connects all the mechanical, electric, and air connections between the truck and trailer, eliminating the need for the standard vulnerable air, electrics and ABS/EBS spiral lines.

The KKS-U basically consists of three parts: the reliable future-proof and ISO 13044-2 compliant standard wedge, the steel spring and the cable box. The newly designed wedge has the familiar KKS connector installed inside. It is attached to the high-quality JOST king pin and rotates around it when cornering. The steel spring encases the supply lines for air, brake and electric safely and reliably. The supply lines are safely stowed in the KKS cable box and are fed into the steel spring when cornering.

“The KKS-U Connector is a unique solution for all trailers that are already in operation. Due to a particularly straightforward installation, they can be effortlessly equipped with the KKS system. No modifications to the trailer chassis are necessary”, said Andreas Jakubin, Product Manager KKS. “Thus, the KKS-U contributes to further savings in time and expenses as well as avoidance of accidents.”

Advantages of the KKS: more efficiency and safety for truck drivers

Using the KKS automatic coupling system can cut the time required to change a trailer by up to 50 percent, as there is no need to manually crank the landing gear, connect the supply lines or open the fifth wheel coupling. The KKS significantly reduces the total costs for each circuit, with savings of up to 50 percent possible during the coupling and uncoupling process. It is particularly well suited for transport companies which perform coupling processes often and drive short distances, such as those in on-site transport, as the time saved here really pays off financially. Another application is the transport of goods where safety plays a key role, such as hazardous goods, as the sensor monitoring guarantees a high level of security against trailer losses and incorrect coupling. The KKS is also an ideal solution for transport between production sites and logistics facilities. Errors or damage caused during the coupling process are eliminated completely thanks to monitoring through the KKS remote control. For example, the Modul E-Drive landing gear is always fully retracted automatically. Moreover, the KKS reduces the probability of trailer losses due to erroneous operation, damage and occupational accidents to virtually zero.

Furthermore, the KKS makes all the physically demanding tasks of the coupling process a thing of the past, as well as ensuring that this process is no longer dependent on the weather or time of day and significantly reducing stress. A standard pneumatic cylinder opens the fifth wheel coupling effortlessly, even when the tractor-trailer is twisted. The automatic coupling process means that the driver does not have to climb in and out of the cab as often, nor climb onto the catwalk between truck and semi-trailer – two factors that significantly reduce the potential for injury. These benefits mean the KKS opens new possibilities for a more diverse driver pool; as such, JOST is providing an answer to demographic change and the lack of specialist workers.

More information on the KKS and KKS-U Connector online at: kks-futurenow.com

About JOST:

JOST is a world-leading producer and supplier of safety-critical systems for the commercial vehicle industry. Under the umbrella brand of JOST, the comprehensive range of products is broken down into systems for applications on the road and in agriculture:

The JOST brand includes fifth wheel couplings, landing gears, ball bearing turntables, king pins and container locks as well as components for alternating systems. Truck and trailer axles are also sold under the JOST brand. The tradition-steeped ROCKINGER brand comprises the core components of towing hitches, drawbar eyes and drawbars for transporters and trucks. TRIDEC offers steering systems and axle suspensions for trailers.

ROCKINGER products are also used in agricultural applications. Quicke has been part of the JOST family since February 2020 and specialises in agricultural front loaders and equipment.

JOST currently employs over 3,600 staff worldwide and has sales and production sites in over 20 countries and on all five continents. JOST has been listed on the Frankfurt Stock Exchange. Further information on JOST can be found here: www.jost-world.com

Press images can be found here: https://www.jost-world.com/en/corporate/mediacenter/press-releases.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Christin Zindritsch
Manager Marketing Communications
christin.zindritsch@jost-world.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye